參考文獻(xiàn)/References:
[1] Wada T,Nakashima T,Hiroshi N,et al.RANKL-RANK signaling in osteoclastogenesis and bone disease[J].Trends Mol Med,2006,12(1):17-25.
[2] Sasaki N,Kusano E.Bone and bone related biochemical examinations.Bone and collagen related metabolites,Measurement and clinical role of OPG[J].Clin Calcium,2006,16(6):956-962.
[3] Yasuda H.Bone and bone related biochemical examinations.Bone and collagen related metabolites.Receptor activator of NF-kappaB ligand(RANKL)[J].Clin Calcium,2006,16(6):964-970.
[4] Blair JM,Zheng Y,Dunstan CR.RANK ligand[J].Int J Biochem Cell Biol,2007,39(6):1077-1081.
[5] Eghbali-Fatourechi G,Khosla S,Sanyal A,et al.Role of RANK ligand in mediating increased bone resorption in early postmenopausal women[J].J Clin Invest,2003,111(8):1221-1230.
[6] Hofbauer LC,Khosla S,Dunstan CR,et al.Estrogen stimulates gene expression and protein production of osteoproteigern in human osteoblastic cells[J].Endorinology,1999,140(9):4367-4370.
[7] Shimizu-Ishiura M,Kawana F,Sasaki T.Osteoprotegerin administration reduces femural bone loss in ovariectomized mice via impairment of osteoclast structure and function[J].J Electron Microsc(Tokyo),2002,51(5):315-325.
[8] 高延征,高坤,沈彬,等.去卵巢后大鼠骨組織中核因子κB受體活化因子配體和骨保護(hù)素表達(dá)的變化[J].中國(guó)組織工程研究與臨床康復(fù),2009,13(15):2877-2881.
[9] Yano K,Tsuda E,Washida N,et al.Immunological characterization of eirculating osteoprotegerin/osteoclastogenesis inhibitory factor:increased serum concentrations in postmenopausal women with osteoporosis[J].J Bone Miner Res,1999,14(4):518-527.
[10] 郭梁.成骨細(xì)胞、破骨細(xì)胞及OPG/RANKL/RANK軸與骨質(zhì)疏松[J].中醫(yī)正骨,2010,22(7):41-44.
[11] Cao J,Venton L,SakataT,et al.Expression of RANKL and OPG correlates with age-related bone loss in male C57BL/6 mice[J].J Bone Miner Res,2003,18(2):270-277.
[12] 李賢讓.護(hù)骨素基因多態(tài)性與老年男性骨質(zhì)疏松癥的關(guān)系[J].山東醫(yī)藥,2009,49(29):71-72.
[13] Van Staa TP,Leufkens HG,Abenhaim,et al.Use of oral corticosteroids and risk of fractures[J].J Bone Miner Res,2000,15(6):993-1000.
[14] Wang FS,Ko JY,Yeh DW,et al.Modulation of Dickkopf-1 attenuates glucocorticoid induction of osteoblast apoptosis,adipocytic differentiation and bonemass loss[J].Endocrinology,2008,149(4):1793-1801.
[15] Drescher W,Weigert KP,Bunger MH,et al.Femoral head blood flow reduction and hypercoagulability under 24h megadose steroid treatment in pigs[J].J Orthop Res,2004,22(3):501-508.
[16] Vidal NO,Brändström H,Jonsson KB,et al.Osteoprotegerin mRNA is expressed in primary human osteoblast-like cell:downregulation by glucocorticoids[J].J Endocrinol,1998,159(1):191-195.
[17] Pierotti S,Gandini L,Lenzi A,et al.Pre-receptorjal regulation of steroid hormonesIn bone cells:insights on glucocorticoid induced osteoporosis[J].J Steroid Biochem Mol Biol,2008,108(3-5):292-299.
[18] Bateman TA,Dunstan CR,Ferguson VL,et al.Osteoprotegerin mitigates tail suspension-induced osteopenia[J].Bone,2000,26(3):443-449.
[19] Miller PD.Anti-resorptives in the management of osteoporosis[J].Best Pract Res Clin Endocrinol Metab,2008,22(5):849-868.
[20] Miller PD,Bolognese MA,Lewiecki EM,et al.Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued,discontinued,and restarting of therapy:a randomized blinded phase 2 clinical trial[J].Bone,2008,43(2):222-229.
[21] Bolon B,Cabpagnuolo G,Feige U.Duration of bone protection by a single osteoprotegerin injection in rats with adjuvant-induced arthritis[J].Cell Mol Life Sci,2002,59(9):1569-1576.
[22] Bekker PJ,Bekker P,Nakanishi A,et al.The effect of a single dose of osteoprotegerin in postmenopausal women[J].J Bone Miner Res,2001,16(2):348-360.
[23] Sinclair AM,Elliott S.Glycoengineering:the effect of glycosylation on the properties of therapeutic proteins[J].J Pharm Sci,2005,94(8):1626-1635.
[24] Fouque-Aubert A,Chapurlat R.Influence of RANKL inhibition on immune system in the treatment of bone disease[J].Joint Bone Spine,2008,75(1):5-10.
[25] Fahrleitner-Pammer A,Dobnig H,Piswanger-Soelkner C,et al.Osteoprotegerin serum levels in women:correlation with age,bone mass,bone turnover and fracture status[J].Wien Klin Wochenschr,2003,115(9):291-297.
[26] Childs LM,Paschalis EP,Xing L,et al.In vivo RANK signaling blockade using the receptor activator of NF-kappaB:Fc effectively prevents and ameliorates wear debris-induced osteolysis via osteoclast depletion without inhibiting osteogenesis[J].J Bone Miner Res,2002,17(2):192-199.
[27] Bekker PJ,Holloway DL,Rasmussen AS,et al.A single-done placebo-controlled study of AMG 162,a fully human monoclonal antibody to RANKL,in postmenopausal women[J].J Bone Miner Res,2005,20(12):2275-2282
[28] Hofhauer LC,Zeitz U,Schoppet M,et a1.Prevention of glucocortieoid induced bone loss in mice by inhibition of RANKL[J].Arthritis Rheum,2009,60(5):1427-1437.
[29] McClung MR,Lewiecki EM,Cohen SB,et al.Denosumab in postmenopausal women with low bone mineral density[J].N Engl J Med,2006,354(8):821-831.
[30] Miller PD.Denosumab:anti-RANKL antibody[J].Curr Osteoporos Rep,2009,7(1):18-22.
[31] Rouxa C,Bolognesed MA,Bianchinc G,et al.Relationship between baseline bone turnover marker levels and percent change in BMD at month 12 in postmenopausal women transitioned to denosumab or contimuing on long-teamalendronate therapy[J].J Bone,2009,(44):476.
[32] 馬培奇.骨質(zhì)疏松癥治療藥物研究概述[J].上海醫(yī)藥,2008,29(5):227-230.